drugset / Trial / NCT02864316
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Phase 2
Terminated
6 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.
Timeline
- Start
- 2016-12
- Primary completion
- 2018-08
- Completion
- 2018-09
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |